Results 111 to 120 of about 17,128 (260)

Response to: "Considerations on the Histologic Definition and Clinical Translation of Burnt-Out MASLD in Resected HCC". [PDF]

Liver Int
Watanabe Y, Aikawa M, Okamoto K, Koyama I.   +3 more
europepmc   +1 more source

Clinical Outcomes After Percutaneous Coronary Intervention in Patients With Cirrhosis: A Multicentre National Study

Alimentary Pharmacology &Therapeutics, EarlyView.
Summary of a multicentre TriNetX study evaluating outcomes after percutaneous coronary intervention (PCI) in patients with cirrhosis. Cirrhosis was associated with higher 1‐year gastrointestinal bleeding and mortality, especially with decompensated disease.
Dhir Gala, Sameer Rao, Manas Gunani, Kajol Shah, Anand V. Kulkarni, Karn Wijarnpreecha, Daniel Q. Huang, Pojsakorn Danpanichkul, Ahmed Al‐Khazraji, Kaveh Hajifathalian, Vivek Lingiah, Paul Gaglio, Nikki Duong, Christine Gerula   +13 more
wiley   +1 more source

Correspondence on Editorial regarding “Identification of signature gene set as highly accurate determination of MASLD progression” [PDF]

Clinical and Molecular Hepatology
Sungju Jung, Sumin Yoon, Jong Hoon Park, Yeon-Su Lee, Kyung Hyun Yoo   +4 more
doaj   +1 more source

Does Burnt-Out MASLD Mark Loss of Hepatic Lipid-Buffering Capacity? [PDF]

Liver Int
Toshikuni N.
europepmc   +1 more source

Review Article: Fibrosis Reversal in Metabolic Dysfunction‐Associated Steatohepatitis—The Promise of Emerging Therapeutics

Alimentary Pharmacology &Therapeutics, EarlyView.
Metabolic dysfunction‐associated steatohepatitis is the second commonest US indication for liver transplantation but remains largely undiagnosed and untreated. Fibrosis stage is the strongest predictor of major adverse liver outcomes, with decompensation rates and transplant‐free survival diverging sharply between F3 and F4, while cardiovascular ...
Malek Ayoub, Tsubasa Tsutsumi, Mary E. Rinella   +2 more
wiley   +1 more source

Inhibition of Acetylation Activity of p300/CBP Ameliorates Hepatic Steatosis Through Downregulation of ACSL4. [PDF]

Liver Int
Cai LY, Guan YP, Hu JH, Sun CY, Ding CH, Zhang X, Zeng X, Xie WF.   +7 more
europepmc   +1 more source

Re‐Evaluating the Comparison of Four Different Ultrasound Elastography Techniques for Diagnosing Advanced Fibrosis

Portal Hypertension &Cirrhosis, EarlyView.
Zain Ul Abedeen, Iqra Alam, Muhammad Atif, Sameer Saleem   +3 more
wiley   +1 more source

Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes

British Journal of Pharmacology, EarlyView.
Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley   +1 more source

Letter to the Editor: When ALT defines the study denominator-MASLD burden or metabolic liver-injury burden? [PDF]

Hepatol Commun
Cheng X, Sun M.
europepmc   +1 more source

Re‐thinking peripheral dysfunctions in obesity: The emerging role of sulphaceutics and sulphanutraceutics

British Journal of Pharmacology, EarlyView.
Obesity is a chronic, relapsing, multisystem disease in which cardiometabolic risk arises from excess adiposity and progressive dysfunction of peripheral organs, ultimately disrupting endocrine and metabolic crosstalk among tissues. Within this network, sulphur‐based biology, centred on hydrogen sulphide and related reactive sulphur species, has ...
Martina Smimmo, Veronica Casale, Roberta d'Emmanuele di Villa Bianca, Valentina Vellecco, Mariarosaria Bucci   +4 more
wiley   +1 more source